ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

This study is currently recruiting participants.
Verified by Infinity Pharmaceuticals, September 2008

Sponsors and Collaborators: Infinity Pharmaceuticals
MedImmune LLC
AstraZeneca
Information provided by: Infinity Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00688766
  Purpose

IPI-504-06 is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of IPI-504 as compared to placebo in patients with metastatic and/or unresectable GIST following failure of at least imatinib and sunitinib.

Approximately 195 patients will be randomized using a 2:1 ratio to receive either IPI-504 (N=130) or placebo (N=65). Upon unblinding, patients receiving either IPI-504 or placebo may receive IPI-504 in the open-label portion of the study if defined inclusion criteria are met.

Early and frequent imaging timepoints (Weeks 2, 5, 8, 14 and every 6 weeks thereafter) are incorporated into this study to capture progression events and limit patient exposure to ineffective agents.


Condition Intervention Phase
Gastrointestinal Stromal Tumors
Drug: retaspimycin hydrochloride (IPI-504)
Drug: placebo
Phase III

MedlinePlus related topics:   Cancer   

ChemIDplus related topics:   Sunitinib    Sunitinib malate    Imatinib    Imatinib mesylate    Dasatinib    IPI-504    17-(Allylamino)-17-demethoxygeldanamycin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib

Further study details as provided by Infinity Pharmaceuticals:

Primary Outcome Measures:
  • Compare the progression free survival (PFS) in both study arms [ Time Frame: Multiple timepoints ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare the disease control rate (DCR) in both arms [ Time Frame: Multiple timepoints ] [ Designated as safety issue: No ]
  • Compare the time to progression (TTP) in both arms [ Time Frame: Multiple timepoints ] [ Designated as safety issue: No ]
  • Compare the overall survival (OS) in both arms [ Time Frame: Continuous ] [ Designated as safety issue: No ]
  • Evaluate the safety and tolerability of IPI-504 in this patient population [ Time Frame: Signing of the informed consent to 30 days after discontinuation of drug ] [ Designated as safety issue: Yes ]

Estimated Enrollment:   195
Study Start Date:   August 2008
Estimated Study Completion Date:   December 2011
Estimated Primary Completion Date:   August 2010 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental
IPI-504 plus best supportive care
Drug: retaspimycin hydrochloride (IPI-504)

IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90).

Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off with best supportive care.

Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.

2: Placebo Comparator
Placebo plus best supportive care
Drug: placebo
30-minute IV infusion twice weekly for 2 weeks followed by 1 week off with best supportive care.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • At least 18 years of age at the time of study randomization.
  • Histologically confirmed metastatic and/or unresectable GIST.
  • Measurable disease on CT or MRI as defined by RECIST.
  • Documented radiographic progression or intolerance to imatinib and sunitinib.
  • Clinical failure of the most recent prior therapy for GIST. Note: There is no limit to the number of prior therapies a patient may have received.
  • Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.
  • Hemoglobin ≥ 8.0 g/dL (80 g/L).
  • Absolute Neutrophil Count ≥ 1500/µL (1.5 x 109/L).
  • Platelets ≥ 100,000 /µL (100 x 109/L).
  • ALT and AST ≤ 2.5 x upper limit of normal (ULN), or ≤ 5.0 x ULN if considered secondary to liver metastases.
  • Alkaline phosphatase ≤ 2.5 x ULN, or ≤ 5.0 x ULN if considered secondary to liver metastases.
  • Serum bilirubin ≤ 1.5 x ULN.
  • PT and PTT ≤ 1.5 x ULN unless the patient is receiving warfarin. If the patient is receiving warfarin, the INR must be within therapeutic range.
  • Serum creatinine ≤ 1.5 x ULN.

Exclusion Criteria:

  • Previous administration of other known heat shock protein 90 (Hsp90) inhibitors.
  • Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease.
  • Initiation or discontinuation of concurrent medication that is a potent CYP3A inhibitor less than 2 weeks prior to administration of IPI-504 or placebo.
  • History of any of the following within the last 6 months: cardiac disease such as acute coronary syndrome or unstable angina, symptomatic congestive heart failure, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any other significant co-morbid condition or disease which, in the judgment of the investigator, would place the patient at undue risk or interfere with the study.
  • Grade 3 or 4 hemorrhagic event within the last 6 months.
  • Known human immunodeficiency virus positivity.
  • Sinus bradycardia (resting heart rate < 50 bpm) secondary to intrinsic conduction system disease.
  • QTcF ≥ 470 milliseconds, or previous history of clinically significant QTc prolongation while taking other medications.
  • History of prior malignancies within the past 3 years other than non-melanomatous skin cancers that have been controlled, prostate cancer that has been treated and has not recurred, non-muscle-invasive bladder cancer, and carcinoma in situ of the cervix.
  • Active or recent history (within 3 months) of keratitis or keratoconjunctivitis confirmed by ophthalmology or optometry exam.
  • Presence of Left Bundle Branch Block, Right Bundle Branch Block plus left anterior hemiblock, bifascicular block, or 3rd degree heart block. This does not include patients with a history of these events with adequate control by pacemaker.
  • Known CNS metastases.
  • Women who are pregnant or lactating.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00688766

Contacts
Contact: GIST Phase 3 Team     877-504-INFI     IPI-504inGIST@infi.com    

Locations
United States, Illinois
Recruiting
      Park Ridge, Illinois, United States, 60068
United States, Massachusetts
Recruiting
      Boston, Massachusetts, United States, 02115
United States, North Carolina
Recruiting
      New Bern, North Carolina, United States, 28562

Sponsors and Collaborators
Infinity Pharmaceuticals
MedImmune LLC
AstraZeneca

Investigators
Study Director:     Robert Shepard, M.D.     Infinity Pharmaceuticals, Inc.    
Principal Investigator:     George Demetri, MD     Dana-Farber Cancer Institute    
  More Information


Click here for more information about this study: Phase 3 Study of IPI-504 in GIST  This link exits the ClinicalTrials.gov site
 

Responsible Party:   Infinity Pharmaceuticals, Inc. ( Project Manager )
Study ID Numbers:   IPI-504-06
First Received:   May 29, 2008
Last Updated:   September 18, 2008
ClinicalTrials.gov Identifier:   NCT00688766
Health Authority:   United States: Food and Drug Administration;   United States: Institutional Review Board

Keywords provided by Infinity Pharmaceuticals:
GIST  
Metastatic and/or Unresectable Gastrointestinal Stromal  

Study placed in the following topic categories:
Imatinib
Digestive System Diseases
Digestive System Neoplasms
Sunitinib
Gastrointestinal Diseases
Dasatinib
Gastrointestinal Neoplasms
Gastrointestinal Stromal Tumors

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Antineoplastic Agents
Growth Substances
Therapeutic Uses
Physiological Effects of Drugs
Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 07, 2008




Links to all studies - primarily for crawlers